In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma

Journal of Pediatric Surgery

Volumn 42, Issue 8, 2007, Pages 1396-1402

  Rodeberg, David A ^a   Erskine, Courtney ^b   Celis, Esteban ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Alveolar rhabdomyosarcoma; Cancer vaccine; Immunotherapy

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 2; TUMOR ANTIGEN;

ALLOGENEIC RESTRICTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL LYSATE; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; EPSTEIN BARR VIRUS; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MELANOMA CELL; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOSARCOMA; STEM CELL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; RHABDOMYOSARCOMA;

EID: 34547764917     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2007.03.041     Document Type: Article

References (46)

1. Arndt C.A.S., and Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341 (1999) 342-352
2. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 (1995) 610-630 [No 3 (March)]
3. Bennett S.R.M., Carbone F.R., Karamalis F., et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186 (1997) 65-70
4. Schuler G., and Steinman R. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186 (1997) 1183-1187
5. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
6. Adema G.J., Hartgers F., and Verstraten R. A dendritic cell derived C-C chemokine that preferentially attracts naive T cells. Nature 387 (1997) 713-717
7. Macatonia S., Hosken N., and Litton M. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154 (1995) 5071-5079
8. Fernandez N., Duffour M.-T., Perricaudet M., et al. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell Mol Ther 4 (1998) 53-65
9. Banchereau J., Palucka A., Dhodapkar M., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 17 (2001) 6451-6458
10. Reichardt V., Okada C., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 7 (1999) 2411-2419
11. Small E., Fratesi P., Reese D., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18 23 (2000) 3894-3903
12. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 11 (1999) 1669-1678
13. Timmerman J., Czerwinski D., Davis T., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 5 (2002) 1517-1526
14. Topalian S. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 6 (1994) 741
15. Lu J., and Celis E. Use of two predictive algorithms of the World Wide Web for the identification of tumor-reactive T-cell epitopes. Cancer Res 60 (2000) 5223-5227
16. Kobayashi H., Wood M., Song Y., et al. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/Neu tumor antigen. Cancer Res 60 (2000) 5228-5236
17. Kobayashi H., Song Y., Hoon D., et al. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61 (2001) 4773-4778
18. Kobayashi H., Omiya R., Ruiz M., et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 8 (2002) 3219-3225
19. Chada S., Mhashilkar A., Roth J., et al. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel 6 2 (2003) 169-173
20. Sarobe P., Huarte E., Lasarte J., et al. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets 4 5 (2004) 443-454
21. Renkvist N., Castelli C., Robbins P., et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50 (2001) 3-15
22. Hubert R.S., Vivanco I., Chen E., et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 96 25 (1999) 14523-14528
23. Yang D., Holt G.E., Velders M.P., et al. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61 15 (2001) 5857-5860
24. Barr F.G., Fitzgerald J.C., Ginsberg J.P., et al. Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res 59 (1999) 5443-5448
25. Scholl F.A., Kamarashev J., Murmann O.V., et al. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61 (2001) 823-826
26. Kotera Y., Shimizu K., and Mule J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61 (2001) 8105-8109
27. Celis E., Tsai V., Crimi C., et al. Induction of antitumor cytotoxic t lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 91 (1994) 2105-2109
28. Lu J., Wettstein P.J., Higashimoto Y., et al. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 166 (2001) 7063-7071
29. Brossart P., Wirths S., Stuhler G., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 9 (2000) 3102-3108
30. Fields R., Shimizu K., and Mule J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95 16 (1998) 9482-9487
31. Herr W., Ranieri E., Olson W., et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. Blood 96 (2000) 1857-1864
32. Boczkowski D., Nair S., Nam J.-H., et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60 4 (2000) 1028-1034
33. Rosenberg S., Yang J., Schwartzentruber D., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 3 (1998) 321-327
34. Huarte E., Sarobe P., Lu J., et al. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res 8 (2002) 2336-2344
35. Smith II J.W., Walker E.B., Fox B.A., et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21 8 (2003) 1562-1573
36. Tsuboi A., Oka Y., Udaka K., et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51 (2002) 614-620
37. Ludewig B., McCoy K., Pericin M., et al. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 166 16 (2001) 3678-3687
38. Jager E., Ringhoffer M., Karbach J., et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8(+) cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66 4 (1996) 470-476
39. Galea-Lauri J., Wells J., Darling D., et al. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53 11 (2004) 963-977
40. Glazyrin A., Kan-Mitchell J., and Mitchell M. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells. Cancer Immunol Immunother 52 3 (2003) 171-178
41. Geiger J., Hutchinson R., Hohenkirk L., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61 (2001) 8513-8519
42. Malmberg K. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?. Cancer Immunol Immunother 53 10 (2004) 879-892
43. Mitchell M. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25 6 (1998) 623-635
44. Hsueh E., Essner R., Foshag L., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20 23 (2002) 4549-4554
45. Toes R., Blom R., van der Voort E., et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56 16 (1996) 3782-3787
46. Jaffee E., Hruban R., Biedrzycki B., et al. Novel allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19 1 (2001) 145-156